Where ARS Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
ARS Pharmaceuticals (NASDAQ:SPRY) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $26.43. The company has shown significant revenue growth but struggles with profitability.
October 08, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ARS Pharmaceuticals has received a mix of bullish and somewhat bullish ratings from analysts, with an average price target increase to $26.43. The company shows strong revenue growth but faces profitability challenges.
The majority of analysts are somewhat bullish on ARS Pharmaceuticals, with a notable increase in the average price target. This suggests positive sentiment and potential for stock price appreciation. However, the company's profitability challenges may temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100